Followers | 2458 |
Posts | 79992 |
Boards Moderated | 0 |
Alias Born | 06/15/2009 |
Friday, January 31, 2020 8:02:35 AM
Recent SNDX News
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 11/01/2024 08:05:00 PM
- Syndax Announces Participation in November Investor Conferences • PR Newswire (US) • 11/01/2024 11:00:00 AM
- Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024 • PR Newswire (US) • 10/29/2024 11:00:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 10/21/2024 08:11:31 PM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 10/04/2024 08:05:00 PM
- Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease • PR Newswire (US) • 09/18/2024 09:15:00 PM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 09/06/2024 08:05:00 PM
- Incyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD) • Business Wire • 08/15/2024 08:15:00 PM
- Incyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD) • Business Wire • 08/15/2024 10:26:00 AM
- Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) • Business Wire • 08/14/2024 09:34:00 PM
- Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia • PR Newswire (US) • 08/12/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 08/05/2024 08:05:00 PM
- Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update • PR Newswire (US) • 08/01/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:04:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:02:10 PM
- Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia • PR Newswire (US) • 07/29/2024 11:01:00 AM
- Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 • PR Newswire (US) • 07/25/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 07/05/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 01:26:27 PM
- Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress • PR Newswire (US) • 06/14/2024 11:00:00 AM
- Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger • GlobeNewswire Inc. • 06/10/2024 11:30:00 AM
- Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC • PR Newswire (US) • 06/06/2024 11:00:00 AM
- Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/05/2024 11:00:00 AM
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 06/03/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:04:25 PM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM